In vitro assessment of the inflammatory breast cancer cell line SUM 149: Discovery of 2 single nucleotidepolymorphisms in the Rnase L gene

Journal of Cancer

Volumn 4, Issue 2, 2013, Pages 104-116

  Nokes, Brandon T ^a   Cunliffe, Heather E ^b   LaFleur, Bonnie ^c   Mount, David W ^a,c   Livingston, Robert B ^a,c   Futscher, Bernard W ^a,c   Lang, Julie E ^d  

^a UNIVERSITY OF ARIZONA   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBONUCLEASE L;

ARTICLE; CANCER CELL; CANCER RISK; CELL LINE; CELL PROLIFERATION; DOSE RESPONSE; GENE FREQUENCY; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IN VITRO STUDY; INFLAMMATORY BREAST CANCER; MISSENSE MUTATION; MOUSE MAMMARY TUMOR ONCOVIRUS; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTHERN BLOTTING; TREATMENT RESPONSE; VIRUS CARCINOGENESIS; VIRUS ETIOLOGY; VIRUS INFECTION; VIRUS REPLICATION;

EID: 84882936550     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.5002     Document Type: Article

References (52)

1. Gonzalez-Angulo AM, Hennessy BT, Broglio K, et al. Trends for inflammatory breast cancer: is survival improving?. Oncologist 2007;12:904-12.
2. Bristol IJ, Woodward WA, Strom EA, et al. Locoregional treatment outcomes after multimodality management of inflammatory breast cancer. Int J Radiat Oncol Biol Phys 2008;72:474-84.
3. Charafe-Jauffret E, Tarpin C, Viens P, Bertucci F. Defining the molecular biology of inflammatory breast cancer. Semin Oncol 2008;35:41-50.
4. Hance KW, Anderson WF, Devesa SS, Young HA, Levine PH. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 2005;97:966-75.
5. Dirix LY, Van Dam P, Prove A, Vermeulen PB. Inflammatory breast cancer: current understanding. Curr Opin Oncol 2006;18:563-71.
6. Singletary SE, Cristofanilli M. Defining the clinical diagnosis of inflammatory breast cancer. Semin Oncol 2008;35:7-10.
7. Dawood S, Merajver SD, Viens P, et al. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 2011;22:515-23.
8. Lerebours F, Bieche I, Lidereau R. Update on inflammatory breast cancer. Breast cancer research : BCR 2005;7:52-8.
9. Tai P, Yu E, Shiels R, et al. Short- and long-term cause-specific survival of patients with inflammatory breast cancer. BMC Cancer 2005;5:137.
10. Cristofanilli M. Novel targeted therapies in inflammatory breast cancer. Cancer 2010;116:2837-9.
11. Dushkin H, Cristofanilli M. Inflammatory breast cancer. J Natl Compr Canc Netw 2011; 9:233-40.
12. Ellis GK, Barlow WE, Gralow JR, et al. Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29:1014-21.
13. Smoot RL, Koch CA, Degnim AC, et al. A single-center experience with inflammatory breast cancer, 1985-2003. Arch Surg 2006;141:567-72.
14. Taghian A, El-Ghamry MN, Merajver SD. Inflammatory breast cancer: Clinical features and treatment. Waltham, MA: Uptodate; 2011.
15. Robertson FM, Bondy M, Yang W, et al. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 2010;60:351-75.
16. Gonzalez-Angulo AM, Sneige N, Buzdar AU, et al. p53 expression as a prognostic marker in inflammatory breast cancer. Clin Cancer Res 2004;10:6215-21.
17. Houchens NW, Merajver SD. Molecular determinants of the inflammatory breast cancer phenotype. Oncology (Williston Park) 2008;22:1556-61.
18. Pogo BG, Melana SM, Holland JF, et al. Sequences homologous to the mouse mammary tumor virus env gene in human breast carcinomacorrelate with overexpression of laminin receptor. Clin Cancer Res 1999;5:2108-11.
19. Fantozzi A, Christofori G. Mouse models of breast cancer metastasis. Breast cancer research : BCR 2006;8:212.
20. Holland JF, Pogo BG. Mouse mammary tumor virus-like viral infection and human breast cancer. Clin Cancer Res 2004;10:5647-9.
21. Fernandez-Cobo M, Melana SM, Holland JF, Pogo BG. Transcription profile of a human breast cancer cell line expressing MMTV-like sequences. Infect Agent Cancer 2006;1:7.
22. Bindra A, Muradrasoli S, Kisekka R, Nordgren H, Warnberg F, Blomberg J. Search for DNA of exogenous mouse mammary tumor virus-related virus in human breast cancer samples. The Journal of general virology 2007;88:1806-9.
23. Mok MT, Lawson JS, Iacopetta BJ, Whitaker NJ. Mouse mammary tumor virus-like env sequences in human breast cancer. Int J Cancer 2008;122:2864-70.
24. Etkind PR, Stewart AF, Wiernik PH. Mouse mammary tumor virus (MMTV)-like DNA sequences in the breast tumors of father, mother, and daughter. Infect Agent Cancer 2008;3:2.
25. Pogo BG, Melana SM, Moran H, Holland JF. Presence of MMTV-like env gene sequences in human breast cancer. Breast Cancer Res Treat 2011;125:295-7.
26. Pogo BG, Holland JF, Levine PH. Human mammary tumor virus in inflammatory breast cancer. Cancer 2010;116:2741-4.
27. Ethier SP, Mahacek ML, Gullick WJ, Frank TS, Weber BL. Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. Cancer Res 1993;53:627-35.
28. Forozan F, Veldman R, Ammerman CA, et al. Molecular cytogenetic analysis of 11 new breast cancer cell lines. Br J Cancer 1999;81:1328-34.
29. Hoffmeyer MR, Wall KM, Dharmawardhane SF. In vitro analysis of the invasive phenotype of SUM 149, an inflammatory breast cancer cell line. Cancer cell international 2005;5:11.
30. Rokman A, Ikonen T, Seppala EH, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet 2002;70:1299-304.
31. Shook SJ, Beuten J, Torkko KC, et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res 2007;13:5959-64.
32. Urisman A, Molinaro RJ, Fischer N, et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog 2006;2:e25.
33. Jin W, Wu DD, Zhang X, Irwin DM, Zhang YP. Positive Selection on the Gene RNASEL: Correlation between Patterns of Evolution and Function. Molecular biology and evolution 2012.
34. De la Vega FM, Lazaruk KD, Rhodes MD, Wenz MH. Assessment of two flexible and compatible SNP genotyping platforms: TaqMan SNP Genotyping Assays and the SNPlex Genotyping System. Mutation research 2005;573:111-35.
35. Boersma BJ, Reimers M, Yi M, et al. A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 2008;122:1324-32.
36. Sen GC. Viruses and interferons. Annu Rev Microbiol 2001;55:255-81.
37. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809.
38. Silverman RH. A scientific journey through the 2-5A/RNase L system. Cytokine & growth factor reviews 2007;18:381-8.
39. Silverman RH. Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol 2007;81:12720-9.
40. Pfeiffer RM, Gail MH. Sample size calculations for population- and family-based case-control association studies on marker genotypes. Genet Epidemiol 2003;25:136-48.
41. Kaiser J. Chronic fatigue syndrome. Studies point to possible contamination in XMRV findings. Science 2011;331:17.
42. Smith RA. Contamination of clinical specimens with MLV-encoding nucleic acids: implications for XMRV and other candidate human retroviruses. Retrovirology 2010;7:112.
43. Pattillo RA, Hussa RO, Story MT, Ruckert AC, Shalaby MR, Mattingly RF. Tumor antigen and human chorionic gonadotropin in CaSki cells: a new epidermoid cervical cancer cell line. Science 1977;196:1456-8.
44. Reuben J. Epstein-Barr Virus (EBV) in Patients with Inflammatory Breast Cancer: A Potential Role in Pathogenesis of the Disease. In: First International Inflammatory Breast Cancer Conference. Houston, Texas: Wiley-Blackwell. 2008.
45. Kaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res 2012;72:3445-50.
46. Pogo BG. Human Mammary Tumor Virus and IBC. In: First International Inflammatory Breast Cancer Conference; 2008; Houston, Texas: Blackwell-Wiley; 2008.
47. Melana SM, Nepomnaschy I, Hasa J, Djougarian A, Holland JF, Pogo BG. Detection of human mammary tumor virus proteins in human breast cancer cells. J Virol Methods 2010;163:157-61.
48. Levine PH, Young H. A, Mark L., Rojowsky H., Holland J. F, Pogo B. G. . Increased detection of breast cancer virus sequences in inflammatory breast cancer. Advances in Tumor Virology 2009; 1:3-7.
49. Stewart A. MMTV-related env sequences in human breast tumor. Int J Cancer 2003;106:138.
50. Park DJ, Southey MC, Giles GG, Hopper JL. No evidence of MMTV-like env sequences in specimens from the Australian Breast Cancer Family Study. Breast Cancer Res Treat 2011;125:229-35.
51. Murakami S, Mizobuchi M, Nakashiro Y, Doi T, Hato N, Yanagihara N. Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Ann Intern Med 1996;124:27-30.
52. Gail MH, Pfeiffer RM, Wheeler W, Pee D. Probability of detecting disease-associated single nucleotide polymorphisms in case-control genome-wide association studies. Biostatistics 2008;9:201-15.